Why the study?
Does the presence of perforin in endomyocardial biopsies predict LVEF deterioration in patients with suspected inflammatory cardiomyopathy?
Population
495 consecutive patients with suspected inflammatory cardiomyopathy undergoing endomyocardial biopsies
Comparison
Detection of perforin in endomyocardial biopsies vs Absence of perforin
Design
Cohort
Follow-up
interquartile range 10.2-37.1 months
Authors
Loading...
Perforin detection in EMBs may stratify LVEF risk in suspected inflammatory cardiomyopathy; leaves open whether EMB-guided therapy improves outcomes.
Does the presence of perforin in endomyocardial biopsies predict LVEF deterioration in patients with suspected inflammatory cardiomyopathy?
The detection of perforin in endomyocardial biopsies is a strong independent predictor of long-term left ventricular ejection fraction deterioration in patients with inflammatory cardiomyopathy.
Escher et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: